Background: Re-Du-Ning inhalation solution (RIS) is a novel preparation derived from the Re-Du-Ning injection, which has been clinically used to treat respiratory diseases such as pneumonia for more than twenty years in China. However, scant reports have been issued on its anti-inflammatory mechanisms. Aim: we investigated the suppressive effect of RIS on inflammatory mediators and explored the underlying mechanism of action.
Introduction
Inammatory responses play an important role in immune homeostasis and are essential for host survival. 1 However, hyperactive and chronic inammation represents a central driving force in many disorders such as asthma, 2 pneumonia, 3 rheumatoid arthritis, 4 and chronic obstructive pulmonary disease. 5 These diseases impose a huge burden on the society in terms of incurred disability and premature mortality. [6] [7] [8] Multiple innate immune cells contribute to the pathophysiological processes of inammatory diseases, with macrophages playing a signicant role.
9 Lipopolysaccharide (LPS) is a pathogenic endotoxin present in the outer membrane of Gram-negative bacteria, which can activate the toll-like receptor (TLR)-4 and the downstream signaling pathways including IKKa/b/IkBa/NFkB, MAPKs/AP-1, and TBK1/IRF3. 10 This in turn activates an inammatory cascade with the production of inammation-related molecules such as nitric oxide (NO), interleukin-6 (IL-6), and tumour necrosis factor (TNF-a), providing a positive feedback to the TLR4 signaling pathways, which results in persistent inammation and favours the induction of autoimmunity.
11-13
Therefore, targeting the TLR4 signaling is one of the focuses in developing effective anti-inammatory agents for acute and chronic inammatory diseases.
14 Traditional Chinese Medicine (TCM) treatment has been recently applied to offer a different approach to prevent or cure inammatory diseases. 15 The Re-Du-Ning inhalation solution (RIS) is a novel preparation derived from the Re-Du-Ning injection (RDNI). The RDNI has been clinically used as an aerosol to treat respiratory diseases such as pneumonia for more than twenty years in the People's Republic of China. 16 This preparation is composed of the owers of Lonicera japonica, the fruits of Gardenia jasminoides, and the dried aerial parts of Artemisia apiacea in the ratio of 25 : 15 : 12. 17 It has been reported that these herbs are of low toxicity and have been used in China for hundreds of years to treat early febrile diseases, exogenous fever, and boils. [18] [19] [20] [21] Previous studies have showed that the main compounds in the owers of Lonicera japonica (e.g. chlorogenic acid), 22, 23 the fruits of Gardenia jasminoides (e.g. geniposide) 10, 24 and Artemisia apiacea (e.g. artemisinin) 25 have strong anti-inammatory activities via inhibition of the TLR4 signaling pathway. However, as a new aerosol preparation, there are no reports in the literature about the pharmacological properties of RIS. In order to provide pharmacological justication for the use of RIS as an anti-inammatory agent, we employed a classic inammatory cell model called the LPSstimulated RAW 264.7 macrophages, to investigate the suppressive effect of RIS on inammatory mediators and to explore the underling mechanisms.
Materials
Modied Griess reagent, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), lipopolysaccharide (LPS, Escherichia coli O55:B5), and bovine serum albumin were bought from Sigma Chemical Co. (St. Louis MO, USA). Penicillin-streptomycin solution was obtained from Caisson labs (Smitheld, UT, USA). Dulbecco's Modied Eagle Medium (DMEM) was acquired from Corning Cellgro (Manassas, VA, USA). Fetal bovine serum (FBS) was purchased from Biological Industries Co. (Beth-Haemek, Israel). Tumor necrosis factor a (TNF-a), interleukin-6 (IL-6), interleukin 1b (IL-1b), macrophage inammatory protein (MIP)-1a, monocyte chemoattractant protein (MCP)-1, and chemokine (C-C motif) ligand 5 (CCL-5) ELISA kits were purchased from Thermo Fisher Scientic (San Diego, CA). Prostaglandin E 2 (PGE 2 ) ELISA kit was provided by Enzo Life Sciences (Exeter, UK). IkB kinase a (IKKa) and sp1 monoclonal antibodies were supplied by Santa Cruz Biotechnology (Santa Cruz, CA, USA). Interferon regulatory factor 3 (IRF3) was purchased from Abcam (Cambridge, UK). Phospho-NF-kB p65 (Ser536), NF-kB p65, phospho-c-Jun (Ser73), c-Jun, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), phospho-IRF3 (Ser396), phospho-IkBa (Ser32), IkBa, phospho-IKKa/b (Ser176/180), phospho-ERK (Thr202/Tyr204), extracellular signal-regulated kinase (ERK), phospho-JNK (Thr183/Tyr185), c-Jun N-terminal kinase (JNK), phospho-p38 (Thr180/Tyr182), p38 mitogen-activated protein kinase (p38), TANK-binding kinase 1 (TBK1), phospho-TBK1 (Ser172), anti-rabbit IgG HRP linked anti-body, and Alexa Fluor 488-conjugated secondary antibody were bought from Cell Signaling Technology (Boston, MA, USA).
Methods

Preparation of RIS powder
RIS (batch number: 170803) was provided by Jiangsu Kanion Pharmaceutical Corporation (Jiangsu, China). RIS (200 mL) was concentrated by rotary evaporation under reduced pressure to remove the solvent. The concentrated extracts were rapidly frozen at À80 C, and then dried in a freeze-dryer (FD-1D-80, Biocool, Beijing, China). The yield of the powdered RIS was 3.87%. To characterize the RIS powder, 0.3542 g of the RIS powder was dissolved with 50% ethanol and diluted to 25 mL. Then, the diluent was ltered through a 0.45 mm Millipore membrane lter for HPLC analysis. To prepare the sample solution for bioassays, RIS was freshly dissolved in DMSO, and then diluted with cell culture medium to various concentrations.
Content determination of RIS powder
For the quality control of the prepared RIS, HPLC analysis was performed using an LC-20a HPLC system (Shimadzu Corporation, Tokyo, Japan) consisting of a vacuum degasser, a quaternary pump, an auto sampler, a thermostatic column compartment, and a diode array detector. The separation was conducted on the Agilent Zorbax SB C18 column (250 mm Â 4.6 mm with 5 mm particle size) with a gradient mobile phase of solvent A (methanol) and solvent B (0.1% phosphoric acid in water). The HPLC elution prole was as follows: 0-10 min, 15-25% A; 10-30 min, 25-35% A; 30-60 min, 35-50% A. The ow rate was maintained at 0.8 mL min À1 and the column temperature was set at 30 C. The chromatograms were monitored with the DAD detector at wavelengths of 237 nm and 324 nm to detect geniposide and chlorogenic acid, respectively. Each sample of 10 mL volume was injected for analysis.
HPLC ngerprint analysis of RIS
In order to obtain comprehensive chemical information of the RIS powder, ngerprint analysis was carried out using a liquid chromatography with the Agilent 1260 LC system (Agilent Technologies, California, USA) equipped with a quaternary pump, autosampler injector, and a DAD detector adjusted to 225 nm. The chromatographic separation was performed on a Phenomenex Luna C 18 column (4.6 Â 150 mm, 5 mm; Phenomenex, Los Angeles, USA) at room temperature. The mobile phase constituted of A (methanol) and B (0.1% phosphoric acid). The gradient elution program was as follows: 0-50 min, 20-60% A; 50-60 min, 60% A. The ow rate was set at 0.8 mL min
À1
. Each sample of 5 mL volume was injected for analysis.
Cell culture
The RAW 264.7 murine macrophage cell line was obtained from American Type Culture Collection (Manassa, VA, USA). Cells were incubated in the DMEM medium at 37 C with 5% CO 2 .
The penicillin/streptomycin antibiotics (1%) and heatinactivated FBS (10%) were added into the DMEM medium. For each experiment, the cells were seeded in plates and allowed to attach for 24 h. Next, the fresh medium supplemented with RIS or the vehicle was substituted in the culture medium.
Cell viability assay
The effect of RIS on the RAW 264.7 cells' viability was measured by the MTT assay. Briey, 6 Â 10 3 cells (100 mL) per well were seeded in 96 well plates and allowed to adhere overnight. Various concentrations of RIS (12.5-400 mg mL
À1
) were added into the cells, incubated for 1 h, and then treated in the presence or absence of LPS (1 mg mL
) for another 24 h. Subsequently, 10 mL of the MTT solution (5 mg mL
) was added in each well and incubated for 3 h at 37 C. The supernatant was then removed and the remaining formazan crystals were dissolved with 100 mL of DMSO in each well. The absorbance at 570 nm was determined using a microplate spectrophotometer (BMG SPECTROstar Nano, Germany). The value of cell viability in the control group was set as 100%. Six replicate wells were used.
Determination of nitric oxide (NO) production
NO production was assayed by measuring nitrite (a stable degradation product of NO) in the supernatants of cultured RAW 264.7 cells using the Griess modied reagent. Briey, 2 Â 10 5 cells per well were seeded in 24 well plates. The volume of cell inoculation was 1 mL. Aer 24 h incubation, the cells were pre-treated with RIS for 1 h, followed by 1 mg mL À1 of LPS, and then incubated in a humidied incubator at 37 C for 24 h. 100 mL of the supernatant was collected, mixed with an equal volume of Griess reagent, and incubated for 10 min at room temperature. The absorbance measured at 540 nm was used as an indication of the nitrite concentration. Sodium nitrite (NaNO 2 ) was used to produce a standard curve of nitrite concentrations. Four replicate wells were used.
Enzyme-linked immunosorbent assay (ELISA)
To measure the production of MIP-1a, MCP-1, TNF-a, IL-6, IL1b, MCP-1, CCL-5, and PGE 2 , the cells were incubated with different concentrations of RIS in either the presence or absence of LPS for 24 h. 100 mL of the culture medium supernatant was collected and the concentrations of proinammatory cytokines and chemokines in the cell culture medium were calculated, based on the concentrations of the standard solution, using ELISA kits according to the manufacturer's instructions. Four replicate wells were used.
Cytoplasmic and nuclear proteins' extraction
Cytoplasmic and nuclear proteins were extracted using the nuclear extraction kit (Solarbio, Beijing, China) according to the manufacturer's instructions. Briey, the RAW 264.7 cells were seeded in 100 mm diameter culture dishes (1 Â 10 6 cells, 10 mL), incubated for 24 h, and then treated with 100 and 200 mg mL À1 of RIS for 1 h. LPS (1 mg mL À1 ) was then added into the culture medium and incubated at 37 C for 60 min. The cells were harvested and washed with PBS. The ice-cold cytoplasmic protein extraction solution was added to separate the cytoplasmic and nuclear proteins aer centrifugation. The same was then added to the nuclear fraction for protein extraction. Three replicates were used.
Western blot analysis
Western blot was performed to explore the underlying mechanism of anti-inammatory action of RIS. Briey, the RAW 264.7 cells were seeded in 60 mm culture dishes (4 Â 10 5 cells, 3 mL) and treated with 100 and 200 mg mL À1 of RIS for 1 h. ), and then xed with formaldehyde in PBS (w/v, 4%) for 15 min. Then, the cells were washed with PBS and permeabilized with Triton X-100 (0.25%) in 30 min at 37 C and blocked for 1 h with BSA (2%). The cells were then incubated with NF-kB/p65 (1 : 300), c-Jun (1 : 300), and IRF3 (1 : 100) overnight at 4 C, respectively. Aer washing with cold PBS, the cells were incubated with Alexa Fluor 488-conjugated secondary antibody (1 : 500) for 1 h at room temperature. The coverslips were mounted using Fluoroshield with DAPI (YESEN, Shanghai, China) and visualized using the Nikon A1R Eclipse Ti confocal microscope (Nikon Corp., Tokyo, Japan).
Statistical analysis
All values were given as the mean AE standard deviation with at least three replicates for each assay. The statistical differences were determined using one-way ANOVA followed by Turkey's multiple comparisons test. When the value of p was below 0.05, the average values of the different groups were considered signicantly different.
The mean contents of chlorogenic acid and geniposide in the RIS powder were 70.03 and 120.50 mg g À1 , respectively.
HPLC ngerprint analysis of RIS
In the HPLC ngerprint analysis of RIS, geniposide was selected as the reference substance. As is shown in Fig. 2 , peak S was geniposide. Except geniposid, other 13 common peaks were conrmed. Table 1 shows the relative retention times and peak area ratios of 13 common peaks and geniposide. Relative retention time means the ratio of the retention time of a common peak to geniposide. Similarly, the peak area ratio is the ratio of the peak area of a common peak to geniposide.
Effect of RIS on cell viability
To determine the sub-cytotoxic concentrations of RIS, the MTT assay was conducted. As shown in Fig. 3 Effect of RIS on the production of NO and PGE2 and the expression of iNOS and COX-2
Next, we determined the inammatory mediators including NO and PGE2 inhibitory activity by RIS in LPS-stimulated RAW 264.7 macrophages. As shown in Fig. 4A and B, the production of NO and PGE 2 was strongly inhibited by RIS in a concentration-dependent manner up to 33% and 70%, respectively, in the RAW 264.7 cells (p < 0.01). Furthermore, we detected the expression of key enzymes responsible for the NO and PGE 2 production including iNOS and COX-2. The LPS-stimulated RAW 264.7 cells strongly upregulated the protein levels of iNOS and COX-2, whereas this effect was notably (p < 0.01) blocked by RIS (100 and 200 mg mL À1 ) in a concentrationdependent manner ( Fig. 4C and E) .
Effect of RIS on the production of pro-inammatory cytokines and chemokines
It has been reported that LPS activates the TLR4 signaling pathway and subsequently produces pro-inammatory cytokines and chemokines in the macrophage cells. 15, 26, 27 In line with the previous studies, we observed that LPS remarkably promoted the release of pro-inammatory cytokines (see Fig. 5D -F, the production of chemokines including MIP-1a, CCL-5, and MCP-1 was signicantly elevated aer the LPS treatment (p < 0.01), indicating that RIS decreased the LPS-induced production of these chemokines (p < 0.05 or p < 0.01) in an effective and concentration-dependent manner.
Effect of RIS on the nuclear translocation of NF-kB, AP-1, and IRF3 in RAW 264.7 cells Following LPS stimulation, NF-kB, AP-1, and IRF3 are activated by post-translational modications, and translocate into the nucleus to induce the transcription of the pro-inammatory cytokines and chemokines.
28,29 Therefore, we rstly investigated the nuclear translocation of these three transcription factors by Western blot analysis. As shown in Fig. 6 , the nuclear protein levels of NF-kB/p65, AP-1/c-Jun, and IRF3 were signicantly up-regulated aer the LPS stimulation, and the RIS treatment markedly reduced the nuclear accumulation of NFkB/p65, AP-1/c-Jun, and IRF3. The cytoplasmic proteins of these transcriptional factors were not signicantly changed aer the RIS treatment.
Next, we performed an immunouorescence assay to examine the nuclear localization of NF-kB/p65, AP-1/c-Jun, and IRF3. We observed that NF-kB/p65, AP-1/c-Jun, and IRF3 were translocated from the cytoplasm to the nucleus aer the LPS treatment, whereas RIS prevented the LPS-induced nuclear translocation in the RAW 264.7 cells (Fig. 7) .
Effect of RIS on the IKKa/b/IkBa/NF-kB, MAPKs/AP-1, and TBK1/IRF3 signaling pathways LPS binds to TLR4 and leads to the activation of NF-kB, AP-1, and IRF3 through the recruitment and activation of the upstream proteins. 24,27 Therefore, we examined the expression of molecular components of TLR4 related pathways in the RAW 264.7 cells. As shown in Fig. 7 and 8 , the phosphorylation levels of IKKa/b and IkBa were signicantly upregulated by the LPS treatment. RIS markedly decreased the LPS-induced elevation of the phosphorylated IKKa/b and IkBa in a concentration-dependent manner. Moreover, the phosphorylation of NF-kB subunit p65 was signicantly increased aer the LPS treatment, whereas RIS strongly exerted the down-regulative effect on the phosphorylated p65, suggesting that RIS inhibited the IKKa/b/IkBa/NF-kB signaling pathway. Furthermore, the phosphorylation levels of MAPKs including p38, ERK, and JNK were signicantly increased aer the LPS stimulation in the RAW 264.7 cells. However, RIS dramatically inhibited the LPS-induced upregulation of these three key protein kinases in a concentration-dependent manner. RIS also reduced the phosphorylation level of the down-stream protein of MAPKs such as the AP-1 subunit c-Jun, indicating that it has a potential inhibitory effect on the MAPKs/AP-1 signaling. In addition, we also observed that RIS notably blocked the LPSinduced, upregulated protein expression of phosphorylated TBK1. The phosphorylation level of IRF3 and the downstream protein of TBK1 were also strongly suppressed by the RIS treatment aer LPS activation, suggesting that the TBK1/IRF3 signaling pathway was also modulated by RIS ( Fig. 8 and 9 ).
Discussion
The anti-inammatory effects and mechanisms of RDNI have been previously reported. 30 In this study, RDNI showed signi-cant suppressive effect on the production of inammatory mediators in the concentration range of 810-6500 mg mL À1 in the LPS-stimulated RAW 264.7 cells. 30 However, RIS exhibited an effective inhibitory effect on the secretion of inammatory mediators in RAW 264.7 cells in the concentration range of 100-200 mg mL À1 . Thus, it could be concluded that RIS had a better anti-inammatory performance than RDNI. Moreover, we did some exploratory work more deeply and comprehensively based on the former research. 30 The nuclear translocation of NF-kB, AP-1, and IRF3 were all studied. The effects of RIS on the three signalling pathways of TLR4 (IKKa/b/ IkBa/NF-kB, MAPKs/AP-1, and TBK1/IRF3) in the LPS induced RAW 264.7 cells were investigated in our study as well.
In the present study, chlorogenic acid and geniposide were identied in freeze dried RIS powder using HPLC analysis. It has been reported that chlorogenic acid inhibits the production of cytokines such as IL-1b, TNF-a, and IL-6 in the LPSstimulated RAW 264.7 cells.
31
It also suppressed the carrageenin-induced paw oedema in rats, which may be related to the inhibitory action on the release of inammatory mediators.
32
Moreover, geniposide also exerted potential antiinammatory activity via inhibition of the NF-kB signaling pathway. 33 Hence, the suppressive effects of RIS on inamma-tory mediators may be, at least in part, due to the presence of these two compounds. Further studies will be conducted to identify other active components responsible for the antiinammatory effect of RIS.
Current drug treatment options against inammation such as NSAID are not satisfactory because of their serious adverse effects and toxicity.
34 Therefore, researchers are seeking new therapeutic agents with high efficacy and safety. In our study, the cell viability was not altered up to 400 mg mL À1 of RIS concentration, suggesting that RIS has relatively low toxicity. Moreover, the upregulation of the inammatory mediators including NO and PGE 2 in the RAW 264.7 cells was suppressed by RIS. Previous reports have shown that the excessive production of NO and PGE 2 by macrophages promotes inammation, immune mediated disorders as well as the symptoms of redness, swelling, and pain. 35, 36 Therefore, the inhibition of NO and PGE 2 by RIS strongly supports its effectiveness and common use in the treatment of inammatory diseases. Furthermore, the key enzymes responsible for the synthesis of NO and PGE 2 are iNOS and COX-2, respectively. 31, 37 In our present study, RIS potentially reduced the LPS induced upregulation of iNOS and COX-2 in the RAW 264.7 cells, showing that the inhibitory effect on the NO and PGE2 production was closely related to the suppression of iNOS and COX-2 expression, respectively.
Several studies have proposed novel strategies for the treatment of inammatory diseases by regulating the activities of macrophages as well as the levels of cytokines (e.g. TNF-a, IL-6, and IL-1b) 38 and chemokines (MCP-1, MIP1-a, and CCL-5).
39 The TLR4 signaling pathway, which regulates the release of pro-inammatory cytokines and chemokines, is believed to be one of the novel therapeutic targets in the treatment of inammatory diseases. [40] [41] [42] Our results showed that RIS effectively decreased the overproduction of TNF-a, IL-6, IL-1b, MCP-1, MIP1-a, and CCL-5 induced by the LPS-treatment in RAW 264.7 cells, suggesting the inhibitory effect of RIS on inammatory mediators. This may contribute to its regulative action on the TLR4 signaling transduction.
Upon ligand binding, TLR4 recruits intracellular adapters including MyD88 and activates the IKK complex (including IKKa, IKKb and IKKg), which phosphorylates the IkB proteins and lead to its ubiquitination and degradation. 43 Subsequently, the NF-kB/p65 complexes are released from IkB and translocate from the cytoplasm to the nucleus. This activates the transcription of a variety of genes participating in the immune and inammatory responses. 44 Our results indicated that RIS signicantly reduced the nuclear translocation and phosphorylation of NF-kB and its upstream kinases including IKKa/b and IkBa in the LPS-treated RAW 264.7 cells, showing that RIS suppressed the IKKa/b/IkBa/NFkB signaling pathway. MAPKs are mainly composed of three characterized subfamilies, namely, ERK1/2, JNK, and p38 MAPK, which stimulate many cellular functions in physiological conditions and are involved in the pathogenesis of many diseases. 45 In response to LPS stimulation, MAPKs are activated through dual phosphorylation of tyrosine and threonine residues, and lead to the activation of AP-1. 46 Our current study suggested that the phosphorylation of MAPKs (ERK1/2, JNK, and p38 MAPK) was suppressed aer the RIS treatment. The nuclear translocation and phosphorylation of AP-1 (c-Jun) was also inhibited by the RIS treatment, revealing that RIS inhibited the MAPKs/AP-1 signaling transduction. In addition to the MyD88-dependent pathways, the TBK1/IRF3 signaling cascade is the main pathway responsible for the induction of type-I interferon production.
47 TBK1 can phosphorylate IRF3 and promotes it nuclear translocation, leading to the expression of IFN-b and CCL-5.
27
Our data represent that the nuclear and phosphorylation levels of IRF3 as well as the phosphorylated TBK1 were decreased by the RIS treatment, indicating that RIS impeded the LPS-induced TBK1/IRF3 axis. 
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Conclusion
The result demonstrates that the suppressive capabilities of RIS on inammatory mediators may be attributed to the inhibition of IKKa/b/IkBa/NF-kB, MAPKs/AP-1, and TBK1/IRF3 signaling pathways in the LPS-stimulated RAW 264.7 cells (Fig. 10) . To further investigate the contribution of the TLR4 related pathways in the anti-inammatory effects of RIS, we will establish animal models to validate it. 
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